Every Form 4 that Avadel Pharmaceuticals plc (AVDL) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow AVDL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AVDL filings page.
Weiss Asset Management LP reported open-market sale transactions in this Form 4 filing.
Weiss Asset Management LP reported a full exit from its indirect stake in AVADEL PHARMACEUTICALS PLC in connection with the company’s acquisition by Alkermes plc. The filing shows 11,112,052 ordinary shares were converted into the right to receive $21.00 per share in cash, plus a contingent value right for an additional $1.50 in cash per share if a specified milestone is achieved. After this transaction, the filing reports 0 shares owned. The shares were held by two private investment funds managed by Weiss Asset Management, which disclaims beneficial ownership beyond its pecuniary interest.
Avadel Pharmaceuticals chief operating officer Susan Rodriguez reported the disposition of 300,000 stock options on February 12, 2026, when Avadel was acquired by Alkermes plc through an Irish court-approved scheme of arrangement.
Each option to buy Avadel ordinary shares at an exercise price of $9.59 was canceled and exchanged for cash equal to the difference between $21.00 and the option’s exercise price per share, plus a non‑transferable contingent value right offering a potential additional $1.50 per share if specified milestones are achieved.
Avadel Pharmaceuticals director Peter J. Thornton reported the cash-out of his equity holdings in connection with Alkermes plc’s acquisition of Avadel. On February 12, 2026, 115,060 Ordinary Shares were disposed of at $21.00 per share in cash, with each share also receiving a contingent value right for a potential additional $1.50 in cash per share upon milestone achievement.
On the same date, multiple stock option awards covering Ordinary Shares, with exercise prices ranging from $2.03 to $16.32 and expirations from 2029 to 2035, were canceled. Each option was exchanged for cash equal to the in-the-money value based on the $21.00 cash consideration per underlying share, plus one contingent value right for each underlying share. Following these transactions, Thornton reported holding no Ordinary Shares or stock options.
Avadel Pharmaceuticals general counsel Jerad G. Seurer reported the automatic disposition of his equity in connection with Alkermes plc’s acquisition of Avadel under a scheme of arrangement.
On February 12, 2026, each outstanding ordinary share was converted into $21.00 in cash plus a non-transferable contingent value right for a potential additional $1.50 per share, subject to milestone achievement. His 23,496 ordinary shares, including previously restricted shares, were treated on the same terms.
On the same date, multiple stock option awards with exercise prices ranging from $4.69 to $13.57 per share were canceled. Each option was exchanged for cash equal to the in-the-money value based on the $21.00 cash consideration, plus one contingent value right for each underlying share.
Avadel Pharmaceuticals director Linda Palczuk reported the automatic disposition of her holdings in connection with Avadel’s acquisition by Alkermes plc under an Irish scheme of arrangement. She disposed of 78,905 Ordinary Shares at $21.00 per share, with each share also receiving a non-transferable contingent value right for a potential additional $1.50 per share.
The filing also shows the disposition of multiple Avadel stock options held by a revocable trust for which she is trustee. At the effective time on February 12, 2026, each outstanding option was cancelled and exchanged for cash equal to the spread over $21.00 per underlying share plus one contingent value right per underlying share, regardless of vesting.
Avadel Pharmaceuticals CFO Thomas S. McHugh reported the disposition of his ordinary shares and stock options in connection with Alkermes plc’s acquisition of the company. At the effective time of the scheme of arrangement, each outstanding ordinary share was converted into $21.00 in cash plus a non-transferable contingent value right for a potential additional $1.50 per share, contingent on specified milestones.
The filing shows 100,400 ordinary shares disposed of at $21.00 per share, leaving no ordinary shares held directly afterward. Multiple stock options covering various numbers of ordinary shares, with exercise prices ranging from $3.45 to $13.57, were canceled and exchanged for cash based on the spread to the $21.00 cash consideration, plus one contingent value right per underlying share.
Avadel Pharmaceuticals director Mark Anthony McCamish reported the automatic disposition of his holdings in connection with the acquisition of Avadel by Alkermes plc under a court-approved scheme of arrangement. His ordinary shares, including those held through a McCamish Charitable Remainder Trust, were converted and no shares remained beneficially owned after the transactions.
At the effective time of the deal on February 12, 2026, each outstanding Avadel ordinary share was exchanged for $21.00 in cash plus a non-transferable contingent value right for a potential additional $1.50 per share, dependent on specified milestones. His outstanding stock options were canceled and exchanged for cash based on the spread between the $21.00 cash consideration and the option exercise prices, and for one contingent value right for each underlying share.
Avadel Pharmaceuticals director Geoffrey Michael Glass reported disposing of his ordinary shares and stock options in connection with Alkermes plc’s acquisition of Avadel. The filing shows that, after these transactions on February 12, 2026, he no longer beneficially owns Avadel securities, whether directly or through trusts.
Under the Transaction Agreement and Irish scheme of arrangement, each outstanding Avadel ordinary share was converted into $21.00 in cash plus a non-transferable contingent value right for a potential additional $1.50 per share, subject to milestone achievement. All outstanding stock options held through trusts were canceled at the effective time and exchanged for cash based on the excess of the $21.00 cash consideration over the option exercise price, plus one CVR for each underlying share.
Avadel Pharmaceuticals director Eric J. Ende reported the cash-out of his equity in connection with the company’s acquisition by Alkermes plc. On February 12, 2026, his 219,905 Ordinary Shares were converted into $21.00 in cash per share plus a non-transferable contingent value right that may pay an additional $1.50 per share if specified milestones are achieved.
On the same date, multiple stock options to buy Ordinary Shares at exercise prices ranging from $1.49 to $16.32, with expirations from 2029 to 2035, were canceled. Each option grant was exchanged for cash based on the spread between the $21.00 cash consideration and the option’s exercise price, plus one contingent value right per underlying share. Following these transactions, Ende reported zero Ordinary Shares and options beneficially owned.
Avadel Pharmaceuticals Chief Executive Officer and director Gregory J. Divis Jr. reported the disposition of all his holdings in connection with the acquisition of Avadel by Alkermes plc. On February 12, 2026, each outstanding Avadel ordinary share was converted into $21.00 in cash plus a non‑transferable contingent value right that may pay an additional $1.50 per share if specified milestones are met.
Divis disposed of 211,105 ordinary shares held directly and 10,000 shares held through the Gregory J. Divis Jr. Revocable Trust. Multiple stock option awards with exercise prices ranging from $1.71 to $13.57, covering various numbers of ordinary shares, were canceled and exchanged for cash equal to their in‑the‑money value plus one contingent value right for each underlying share. After these transactions, the filing shows no ordinary shares or options beneficially owned.
Avadel Pharmaceuticals director Amin Naseem reported dispositions of all Avadel holdings in connection with the company’s acquisition by Alkermes. On February 12, 2026, 22,000 Ordinary Shares were converted into $21.00 in cash per share plus a potential $1.50 per-share contingent value right.
The filing also shows cancellation of stock options covering 49,500, 11,000 and 11,000 Ordinary Shares. Each option was exchanged for cash based on the spread over the $21.00 cash consideration and one contingent value right per underlying share.
Avadel Pharmaceuticals director Mark Anthony McCamish reported an internal share transfer involving 67,025 ordinary shares on February 4, 2026. The filing shows 67,025 shares moved from Matthew 5 LLC to the McCamish Charitable Remainder Trust at a stated price of $0 per share.
Following these transactions, 67,025 ordinary shares are reported as indirectly held through the McCamish Charitable Remainder Trust and 22,000 ordinary shares are reported as directly held. The reporting person and his spouse are income beneficiaries of the charitable remainder trust, and he disclaims beneficial ownership except for his and his spouse's pecuniary interest.